Western firms show growing interest in traditional Chinese medicine

03/27/2013 | China Daily (Beijing)

Pharmaceutical firms from Europe, Japan, South Korea and the United States are investing in the development of medications and treatments derived from traditional Chinese medicine. GlaxoSmithKline, for example, recently announced a traditional Chinese medicine program based in Shanghai that will target both a Chinese and global market. "Our priority is to transform TCM from an experience-based practice to evidence-based medicines through innovation and differentiation," said Jingwu Zang, head of R&D for GlaxoSmithKline in China.

View Full Article in:

China Daily (Beijing)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN